BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Manns MP, Buti M, Gane E, Pawlotsky JM, Razavi H, Terrault N, Younossi Z. Hepatitis C virus infection. Nat Rev Dis Primers. 2017;3:17006. [PMID: 28252637 DOI: 10.1038/nrdp.2017.6] [Cited by in Crossref: 189] [Cited by in F6Publishing: 162] [Article Influence: 37.8] [Reference Citation Analysis]
Number Citing Articles
1 Valadkhan S, Fortes P. Regulation of the Interferon Response by lncRNAs in HCV Infection. Front Microbiol 2018;9:181. [DOI: 10.3389/fmicb.2018.00181] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
2 Shabangu CS, Siphepho PY, Li CY, Cheng WC, Lu MY, Huang CF, Yeh ML, Dai CY, Huang JF, Chuang WL, Lin ZY, Yu ML, Wang SC. The Persistence of Hepatitis C Virus Infection in Hepatocytes Promotes Hepatocellular Carcinoma Progression by Pro-Inflammatory Interluekin-8 Expression. Biomedicines 2021;9:1446. [PMID: 34680563 DOI: 10.3390/biomedicines9101446] [Reference Citation Analysis]
3 Schulze RJ, Schott MB, Casey CA, Tuma PL, McNiven MA. The cell biology of the hepatocyte: A membrane trafficking machine. J Cell Biol 2019;218:2096-112. [PMID: 31201265 DOI: 10.1083/jcb.201903090] [Cited by in Crossref: 26] [Cited by in F6Publishing: 18] [Article Influence: 8.7] [Reference Citation Analysis]
4 Montasser IF, Ibrahim AA, Farid HM, Al Balakosy AM. De novo hepatocellular carcinoma in cirrhotic hepatitis C virus: Are directly acting antivirals beneficial? Clin Res Hepatol Gastroenterol 2021;45:101517. [PMID: 32900667 DOI: 10.1016/j.clinre.2020.07.022] [Reference Citation Analysis]
5 Beyaz Coşkun A, Sağdiçoğlu Celep AG. Therapeutic modulation methods of gut microbiota and gut-liver axis. Crit Rev Food Sci Nutr 2021;:1-11. [PMID: 33749411 DOI: 10.1080/10408398.2021.1902263] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Ku J, Kim S, Park J, Kim TS, Kharbash R, Shin EC, Char K, Kim Y, Li S. Reactive Polymer Targeting dsRNA as Universal Virus Detection Platform with Enhanced Sensitivity. Biomacromolecules 2020;21:2440-54. [PMID: 32233463 DOI: 10.1021/acs.biomac.0c00379] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
7 Rios DA, Valva P, Casciato PC, Frias S, Soledad Caldirola M, Gaillard MI, Bezrodnik L, Bandi J, Galdame O, Ameigeiras B, Krasniansky D, Brodersen C, Mullen E, Matteo EN, Preciado MV. Chronic hepatitis C liver microenvironment: role of the Th17/Treg interplay related to fibrogenesis. Sci Rep. 2017;7:13283. [PMID: 29038590 DOI: 10.1038/s41598-017-13777-3] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
8 Ikram A, Zaheer T, Awan FM, Obaid A, Naz A, Hanif R, Paracha RZ, Ali A, Naveed AK, Janjua HA. Exploring NS3/4A, NS5A and NS5B proteins to design conserved subunit multi-epitope vaccine against HCV utilizing immunoinformatics approaches. Sci Rep 2018;8:16107. [PMID: 30382118 DOI: 10.1038/s41598-018-34254-5] [Cited by in Crossref: 44] [Cited by in F6Publishing: 38] [Article Influence: 11.0] [Reference Citation Analysis]
9 Wu L, Luo PP, Tian YH, Chen LY, Zhang YL. Clinical efficacy of thymosin alpha 1 combined with multi-modality chemotherapy and its effects on immune function of patients with pulmonary tuberculosis complicated with diabetes. Pak J Med Sci 2022;38:179-84. [PMID: 35035422 DOI: 10.12669/pjms.38.1.4419] [Reference Citation Analysis]
10 Hopkins L, Dunlap T, Cline H. Pharmacology Update for the Treatment of Hepatitis C Virus. Nurs Clin North Am 2020;55:347-59. [PMID: 32762855 DOI: 10.1016/j.cnur.2020.06.008] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
11 Proskynitopoulos PJ, Rhein M, Jäckel E, Manns MP, Frieling H, Bleich S, Thum T, Hillemacher T, Glahn A. Leptin Expression and Gene Methylation Patterns in Alcohol-Dependent Patients with Ethyltoxic Cirrhosis—Normalization After Liver Transplantation and Implications for Future Research. Alcohol and Alcoholism 2018;53:511-7. [DOI: 10.1093/alcalc/agy038] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
12 Tenge VR, Murakami K, Salmen W, Lin SC, Crawford SE, Neill FH, Prasad BVV, Atmar RL, Estes MK. Bile Goes Viral. Viruses 2021;13:998. [PMID: 34071855 DOI: 10.3390/v13060998] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
13 El-Miligy MM, Rida SM, Ashour FA, Badr MH, El-Bassiony EM, El-Demellawy MA, Omar AM. Dual inhibitors of hepatitis C virus and hepatocellular carcinoma: design, synthesis and docking studies. Future Sci OA 2018;4:FSO252. [PMID: 29255624 DOI: 10.4155/fsoa-2017-0075] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
14 Sohn W. Direct-acting antivirals trigger a favorable, sustained virological response in patients with chronic hepatitis C infections and hepatocellular carcinoma. Korean J Intern Med 2021;36:286-7. [PMID: 33725434 DOI: 10.3904/kjim.2021.078] [Reference Citation Analysis]
15 Mensa FJ, Lovell S, Pilot-Matias T, Liu W. Glecaprevir/pibrentasvir for the treatment of chronic hepatitis C virus infection. Future Microbiol 2019;14:89-110. [PMID: 30499343 DOI: 10.2217/fmb-2018-0233] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
16 Mura G, Chessa L, Manca A, Preti A, Balestrieri C, Onali S, Carta MG. Impact of direct-acting antiviral drugs for chronic hepatitis C on mood: Preliminary results from a longitudinal study. General Hospital Psychiatry 2019;56:50-1. [DOI: 10.1016/j.genhosppsych.2018.10.008] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
17 Müller-coan BG, Caetano BFR, Pagano JS, Elgui de Oliveira D. Cancer Progression Goes Viral: The Role of Oncoviruses in Aggressiveness of Malignancies. Trends in Cancer 2018;4:485-98. [DOI: 10.1016/j.trecan.2018.04.006] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
18 Rao BC, Lou JM, Wang WJ, Li A, Cui GY, Yu ZJ, Ren ZG. Human microbiome is a diagnostic biomarker in hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int 2020;19:109-15. [PMID: 32037278 DOI: 10.1016/j.hbpd.2020.01.003] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
19 Qian X, Xu C, Wu B, Tang H, Zhao P, Qi Z. SNORD126 Promotes Hepatitis C Virus Infection by Upregulating Claudin-1 via Activation of PI3K-AKT Signaling Pathway. Front Microbiol 2020;11:565590. [PMID: 33042070 DOI: 10.3389/fmicb.2020.565590] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
20 Ceccherini-Silberstein F, Cento V, Di Maio VC, Perno CF, Craxì A. Viral resistance in HCV infection. Curr Opin Virol 2018;32:115-27. [PMID: 30439589 DOI: 10.1016/j.coviro.2018.10.005] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
21 Gruden Š, Poklar Ulrih N. Diverse Mechanisms of Antimicrobial Activities of Lactoferrins, Lactoferricins, and Other Lactoferrin-Derived Peptides. Int J Mol Sci 2021;22:11264. [PMID: 34681923 DOI: 10.3390/ijms222011264] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 Jogezai N, Shabbir MI. A hand-held device for rapid single tube detection of hepatitis-C virus. Anal Methods 2018;10:4233-41. [DOI: 10.1039/c8ay00802g] [Cited by in Crossref: 7] [Article Influence: 1.8] [Reference Citation Analysis]
23 Yeung KS, Beno BR, Mosure K, Zhu J, Grant-Young KA, Parcella K, Anjanappa P, Bora RO, Selvakumar K, Wang YK, Fang H, Krause R, Rigat K, Liu M, Lemm J, Sheriff S, Witmer M, Tredup J, Jardel A, Kish K, Parker D, Haskell R, Santone K, Meanwell NA, Soars MG, Roberts SB, Kadow JF. Structure-Property Basis for Solving Transporter-Mediated Efflux and Pan-Genotypic Inhibition in HCV NS5B Inhibitors. ACS Med Chem Lett 2018;9:1217-22. [PMID: 30613329 DOI: 10.1021/acsmedchemlett.8b00379] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
24 Marecki JC, Aarattuthodiyil S, Byrd AK, Penthala NR, Crooks PA, Raney KD. N-Naphthoyl-substituted indole thio-barbituric acid analogs inhibit the helicase activity of the hepatitis C virus NS3. Bioorg Med Chem Lett 2019;29:430-4. [PMID: 30578035 DOI: 10.1016/j.bmcl.2018.12.026] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
25 Chigbu DI, Loonawat R, Sehgal M, Patel D, Jain P. Hepatitis C Virus Infection: Host⁻Virus Interaction and Mechanisms of Viral Persistence. Cells 2019;8:E376. [PMID: 31027278 DOI: 10.3390/cells8040376] [Cited by in Crossref: 36] [Cited by in F6Publishing: 34] [Article Influence: 12.0] [Reference Citation Analysis]
26 Khanizadeh S, Hasanvand B, Esmaeil Lashgarian H, Almasian M, Goudarzi G. Interaction of viral oncogenic proteins with the Wnt signaling pathway. Iran J Basic Med Sci. 2018;21:651-659. [PMID: 30140402 DOI: 10.22038/ijbms.2018.28903.6982] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
27 Wang YZ, Li JL, Wang X, Zhang T, Ho WZ. (-)-Epigallocatechin-3-gallate enhances poly I:C-induced interferon-λ1 production and inhibits hepatitis C virus replication in hepatocytes. World J Gastroenterol 2017; 23(32): 5895-5903 [PMID: 28932081 DOI: 10.3748/wjg.v23.i32.5895] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
28 Martinello M, Yee J, Bartlett SR, Read P, Baker D, Post JJ, Finlayson R, Bloch M, Doyle J, Shaw D, Hellard M, Petoumenos K, Lin L, Marks P, Applegate T, Dore GJ, Matthews GV. Moving Towards Hepatitis C Microelimination Among People Living With Human Immunodeficiency Virus in Australia: The CEASE Study. Clinical Infectious Diseases 2020;71:1502-10. [DOI: 10.1093/cid/ciz985] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 4.7] [Reference Citation Analysis]
29 Ke PY. The Multifaceted Roles of Autophagy in Flavivirus-Host Interactions. Int J Mol Sci 2018;19:E3940. [PMID: 30544615 DOI: 10.3390/ijms19123940] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 6.0] [Reference Citation Analysis]
30 Zhang Y, Chen S, Yuan Z, Yi Z. Bioorthogonal dissection of the replicase assembly of hepatitis C virus. Cell Chem Biol 2021:S2451-9456(21)00145-8. [PMID: 33798447 DOI: 10.1016/j.chembiol.2021.03.006] [Reference Citation Analysis]
31 Ponvilawan B, Charoenngam N, Rujirachun P, Wattanachayakul P, Tornsatitkul S, Rittiphairoj T, Ungprasert P. Chronic Hepatitis C Virus Infection is Associated with an Increased Risk of Lung Cancer: A Systematic Review and Meta-analysis. Lung 2020;198:705-14. [DOI: 10.1007/s00408-020-00365-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
32 Kim T, Noh S, Ree Kim Y, Lee C, Eon Kim J, Jeong C, Yoon K. Development and validation of a management system and dataset quality assessment tool for the Radiology Common Data Model (R_CDM): A case study in liver disease. International Journal of Medical Informatics 2022. [DOI: 10.1016/j.ijmedinf.2022.104759] [Reference Citation Analysis]
33 Tacke F, Boeker KHW, Klinker H, Heyne R, Buggisch P, Pathil A, Wiegand J, Cornberg M, Lange C, Berg T, Zeuzem S, Mauss S. Baseline risk factors determine lack of biochemical response after SVR in chronic hepatitis C patients treated with DAAs. Liver Int 2020;40:539-48. [PMID: 31241820 DOI: 10.1111/liv.14186] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
34 Salehi S, Tavabie OD, Verma S, McPhail MJW, Farzaneh F, Bernal W, Menon K, Agarwal K, Aluvihare VR. Serum MicroRNA Signatures in Recovery From Acute and Chronic Liver Injury and Selection for Liver Transplantation. Liver Transpl 2020;26:811-22. [PMID: 32297687 DOI: 10.1002/lt.25781] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
35 López-Osorio MC, Beltrán M, Navas MC. [Epidemiology of hepatitis C virus infection in ColombiaEpidemiologia da infecção pelo vírus da hepatite C na Colômbia]. Rev Panam Salud Publica 2021;45:e96. [PMID: 34539763 DOI: 10.26633/RPSP.2021.96] [Reference Citation Analysis]
36 Alothaid H, Aldughaim MSK, El Bakkouri K, AlMashhadi S, Al-Qahtani AA. Similarities between the effect of SARS-CoV-2 and HCV on the cellular level, and the possible role of ion channels in COVID19 progression: a review of potential targets for diagnosis and treatment. Channels (Austin) 2020;14:403-12. [PMID: 33092458 DOI: 10.1080/19336950.2020.1837439] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
37 Santos TPS, Pereira MM, Schinoni MI, Sampaio GP, Aras R Jr, Atta MLS, Atta AM. Atherogenic cytokines and chemokines in chronic hepatitis C are not associated with the presence of cardiovascular diseases. Cytokine 2019;115:24-31. [PMID: 30771700 DOI: 10.1016/j.cyto.2018.12.005] [Reference Citation Analysis]
38 Younossi ZM, Tanaka A, Eguchi Y, Henry L, Beckerman R, Mizokami M. Treatment of hepatitis C virus leads to economic gains related to reduction in cases of hepatocellular carcinoma and decompensated cirrhosis in Japan. J Viral Hepat 2018;25:945-51. [DOI: 10.1111/jvh.12886] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
39 Manns MP, Burra P, Sargent J, Horton R, Karlsen TH. The Lancet-EASL Commission on liver diseases in Europe: overcoming unmet needs, stigma, and inequities. Lancet 2018;392:621-2. [PMID: 30060999 DOI: 10.1016/S0140-6736(18)31734-3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
40 Martinello M, Bhagani S, Gane E, Orkin C, Cooke G, Dore GJ, Petoumenos K, Applegate TL, Tu E, Marks P, Pagani N, Grebely J, Nelson M, Matthews GV. Shortened therapy of eight weeks with paritaprevir/ritonavir/ombitasvir and dasabuvir is highly effective in people with recent HCV genotype 1 infection. J Viral Hepat 2018;25:1180-8. [DOI: 10.1111/jvh.12917] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 3.5] [Reference Citation Analysis]
41 Viola L, Marciano S, Colombato L, Coelho H, Cheinquer H, Bugarin G, Tatsch F, Carvalho-Filho RJ, Roblero JP, Varon A, Holguin J, Torres-Ibarra MR, Pérez-Ríos AM. HEPLA: A multicenter study on demographic and disease characteristics of patients with hepatitis C in Latin America. Ann Hepatol 2020;19:161-5. [PMID: 31718995 DOI: 10.1016/j.aohep.2019.09.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
42 Mohammadzadeh I, Qujeq D, Yousefi T, Ferns GA, Maniati M, Vaghari-Tabari M. CRISPR/Cas9 gene editing: A new therapeutic approach in the treatment of infection and autoimmunity. IUBMB Life. 2020;72:1603-1621. [PMID: 32344465 DOI: 10.1002/iub.2296] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
43 Kitane DL, Loukman S, Marchoudi N, Fernandez-Galiana A, El Ansari FZ, Jouali F, Badir J, Gala JL, Bertsimas D, Azami N, Lakbita O, Moudam O, Benhida R, Fekkak J. A simple and fast spectroscopy-based technique for Covid-19 diagnosis. Sci Rep 2021;11:16740. [PMID: 34408169 DOI: 10.1038/s41598-021-95568-5] [Reference Citation Analysis]
44 Zhang C, Wang XM, Li SR, Twelkmeyer T, Wang WH, Zhang SY, Wang SF, Chen JZ, Jin X, Wu YZ, Chen XW, Wang SD, Niu JQ, Chen HR, Tang H. NKG2A is a NK cell exhaustion checkpoint for HCV persistence. Nat Commun 2019;10:1507. [PMID: 30944315 DOI: 10.1038/s41467-019-09212-y] [Cited by in Crossref: 47] [Cited by in F6Publishing: 49] [Article Influence: 15.7] [Reference Citation Analysis]
45 Sekulic S, Mijailovic Z, Petrovic D, Lukic R, Jovanovic M, Jovanovic I. HCV Infection and Chronic Renal Disease. Serbian Journal of Experimental and Clinical Research 2021;0:000010247820210010. [DOI: 10.2478/sjecr-2021-0010] [Reference Citation Analysis]
46 Singh AD, Maitra S, Singh N, Tyagi P, Ashraf A, Kumar R, Shalimar. Systematic review with meta-analysis: impact of baseline resistance-associated substitutions on the efficacy of glecaprevir/pibrentasvir among chronic hepatitis C patients. Aliment Pharmacol Ther 2020;51:490-504. [PMID: 31943236 DOI: 10.1111/apt.15633] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
47 de Brito RJVC, da Silva LF, Santos MB, de Moura PMMF, de Souza CDF, do Carmo RF. A time series analysis of detection and mortality of hepatitis C in Brazil, 2008–2018. BMC Infect Dis 2022;22. [DOI: 10.1186/s12879-022-07063-5] [Reference Citation Analysis]
48 Huang X, Glessner JT, Huang J, Zhou D, March ME, Wang H, Xia Q, Hakonarson H, Li J. Discovery of Novel Host Molecular Factors Underlying HBV/HCV Infection. Front Cell Dev Biol 2021;9:690882. [PMID: 34458256 DOI: 10.3389/fcell.2021.690882] [Reference Citation Analysis]
49 Öksüz Z, Üçbilek E, Serin MS, Yaraş S, Temel GÖ, Sezgin O. hsa-miR-17-5p: A Possible Predictor of Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir ± Ribavirin Therapy Efficacy in Hepatitis C Infection. Curr Microbiol 2022;79:186. [PMID: 35524830 DOI: 10.1007/s00284-022-02882-w] [Reference Citation Analysis]
50 Cao L, Yu B, Kong D, Cong Q, Yu T, Chen Z, Hu Z, Chang H, Zhong J, Baker D, He Y. Functional expression and characterization of the envelope glycoprotein E1E2 heterodimer of hepatitis C virus. PLoS Pathog 2019;15:e1007759. [PMID: 31116791 DOI: 10.1371/journal.ppat.1007759] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 4.7] [Reference Citation Analysis]
51 Shiode Y, Hikita H, Tanaka S, Shirai K, Doi A, Sakane S, Kai Y, Nakabori T, Yamada R, Kodama T, Narumi R, Sakamori R, Eguchi H, Tomonaga T, Tatsumi T, Takehara T. Hepatitis C virus enhances Rubicon expression, leading to autophagy inhibition and intracellular innate immune activation. Sci Rep 2020;10:15290. [PMID: 32943718 DOI: 10.1038/s41598-020-72294-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
52 Lee A, Hanson J, Fox P, Spice G, Russell D, Boyd P. A decentralised, multidisciplinary model of care facilitates treatment of hepatitis C in regional Australia. Journal of Virus Eradication 2018;4:160-4. [DOI: 10.1016/s2055-6640(20)30270-3] [Cited by in Crossref: 8] [Article Influence: 2.0] [Reference Citation Analysis]
53 Mogalian E, Brainard DM, Osinusi A, Moorehead L, Murray B, Ling KHJ, Perry R, Curtis C, Lawitz E, Lasseter K, Marbury T, Mathias A. Pharmacokinetics and Safety of Velpatasvir and Sofosbuvir/Velpatasvir in Subjects with Hepatic Impairment. Clin Pharmacokinet 2018;57:1449-57. [DOI: 10.1007/s40262-018-0645-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
54 Yang L, Wang R, Yang S, Ma Z, Lin S, Nan Y, Li Q, Tang Q, Zhang YJ. Karyopherin Alpha 6 Is Required for Replication of Porcine Reproductive and Respiratory Syndrome Virus and Zika Virus. J Virol 2018;92:e00072-18. [PMID: 29444946 DOI: 10.1128/JVI.00072-18] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
55 Rios DA, Casciato PC, Caldirola MS, Gaillard MI, Giadans C, Ameigeiras B, De Matteo EN, Preciado MV, Valva P. Chronic Hepatitis C Pathogenesis: Immune Response in the Liver Microenvironment and Peripheral Compartment. Front Cell Infect Microbiol 2021;11:712105. [PMID: 34414132 DOI: 10.3389/fcimb.2021.712105] [Reference Citation Analysis]
56 Martinello M, Dore GJ, Matthews GV, Grebely J. Strategies to Reduce Hepatitis C Virus Reinfection in People Who Inject Drugs. Infect Dis Clin North Am 2018;32:371-93. [PMID: 29778261 DOI: 10.1016/j.idc.2018.02.003] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 5.3] [Reference Citation Analysis]
57 Ahmed S, Ullah N, Parveen S, Javed I, Jalil NAC, Murtey MD, Sheikh IS, Khan S, Ojha SC, Chen K, Xiao J. Effect of Silymarin as an Adjunct Therapy in Combination with Sofosbuvir and Ribavirin in Hepatitis C Patients: A Miniature Clinical Trial. Oxidative Medicine and Cellular Longevity 2022;2022:1-14. [DOI: 10.1155/2022/9199190] [Reference Citation Analysis]
58 Pradhan-Sundd T, Monga SP. Blood-Bile Barrier: Morphology, Regulation, and Pathophysiology. Gene Expr 2019;19:69-87. [PMID: 30646969 DOI: 10.3727/105221619X15469715711907] [Cited by in Crossref: 13] [Cited by in F6Publishing: 5] [Article Influence: 4.3] [Reference Citation Analysis]
59 Néant N, Solas C. Drug-Drug Interactions Potential of Direct-Acting Antivirals for the treatment of Chronic Hepatitis C Virus infection. Int J Antimicrob Agents 2020;56:105571. [PMID: 30394302 DOI: 10.1016/j.ijantimicag.2018.10.014] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
60 Gibriel AA, Al-anany AM, Al-arab MAE, Azzazy HME. Investigating circulatory microRNA expression profiles in Egyptian patients infected with hepatitis C virus mediated hepatic disorders. Meta Gene 2020;26:100792. [DOI: 10.1016/j.mgene.2020.100792] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
61 Lothert K, Offersgaard AF, Pihl AF, Mathiesen CK, Jensen TB, Alzua GP, Fahnøe U, Bukh J, Gottwein JM, Wolff MW. Development of a downstream process for the production of an inactivated whole hepatitis C virus vaccine. Sci Rep 2020;10:16261. [PMID: 33004836 DOI: 10.1038/s41598-020-72328-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
62 Marecki JC, Belachew B, Gao J, Raney KD. RNA helicases required for viral propagation in humans. Enzymes 2021;50:335-67. [PMID: 34861942 DOI: 10.1016/bs.enz.2021.09.005] [Reference Citation Analysis]
63 da Motta LR, Adami AG, Sperhacke RD, Kato SK, Paganella MP, Pereira GFM, Benzaken AS. Hepatitis B and C prevalence and risk factors among young men presenting to the Brazilian Army: A STROBE-compliant national survey-based cross-sectional observational study. Medicine (Baltimore). 2019;98:e16401. [PMID: 31393348 DOI: 10.1097/md.0000000000016401] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
64 Hauck F, Voss R, Urban C, Seidel MG. Intrinsic and extrinsic causes of malignancies in patients with primary immunodeficiency disorders. Journal of Allergy and Clinical Immunology 2018;141:59-68.e4. [DOI: 10.1016/j.jaci.2017.06.009] [Cited by in Crossref: 56] [Cited by in F6Publishing: 51] [Article Influence: 14.0] [Reference Citation Analysis]
65 Sarrazin C, Zimmermann T, Berg T, Hinrichsen H, Mauss S, Wedemeyer H, Zeuzem S; Deutsche Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS)., Deutsche Gesellschaft für Pathologie e. V. (DGP) und Bundesverband Deutscher Pathologen (BDP)., Deutsche Leberstiftung., Gesellschaft für Virologie e. V. (GfV)., Gesellschaft für Pädiatrische Gastroenterologie und Ernährung (GPGE)., Österreichische Gesellschaft für Gastroenterologie und Hepatologie (ÖGGH)., Schweizerische Gesellschaft für Gastroenterologie (SGG)., Deutsche Transplantationsgesellschaft e. V. (DTG)., Deutsche Leberhilfe e. V., Deutsche Gesellschaft für Infektiologie e. V. (DGI)., Deutsche Gesellschaft für Suchtmedizin e. V. (DGS)., Deutsche AIDS-Gesellschaft e. V. (DAIG)., Deutsche Arbeitsgemeinschaft niedergelassener Ärzte für die Versorgung HIV-Infizierter (DAGNÄ)., Robert Koch-Institut (RKI)., Collaborators:. Prophylaxe, Diagnostik und Therapie der Hepatitis-C-Virus(HCV)-Infektion. Z Gastroenterol 2020;58:1110-31. [PMID: 33197953 DOI: 10.1055/a-1226-0241] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
66 Coleman WB, Tsongalis GJ. Understanding molecular pathogenesis: the biological basis of human disease and implications for improved treatment of human disease. Essential Concepts in Molecular Pathology. Elsevier; 2020. pp. 191-200. [DOI: 10.1016/b978-0-12-813257-9.00012-7] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
67 Han W, Li J, Zhou H, Qian J, Tong Z, Wang W, Zhong J, Xue T, Chen Q, Yao Y, Shao S. Identification of the association of CD28+ CD244+ Tc17/IFN-γ cells with chronic hepatitis C virus infection. J Med Virol 2020. [PMID: 32568409 DOI: 10.1002/jmv.26205] [Reference Citation Analysis]
68 Yager EJ, Konan KV. Sphingolipids as Potential Therapeutic Targets against Enveloped Human RNA Viruses. Viruses 2019;11:E912. [PMID: 31581580 DOI: 10.3390/v11100912] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
69 Hupa KL, Jaeckel E, Manns MP. Silymarin for Treatment of Nonalcoholic Steatohepatitis-A New Kid on the Block? Clin Gastroenterol Hepatol 2017;15:1863-5. [PMID: 28804034 DOI: 10.1016/j.cgh.2017.08.005] [Reference Citation Analysis]
70 Gálvez JA, Clavería-gimeno R, Galano-frutos JJ, Sancho J, Velázquez-campoy A, Abian O, Díaz-de-villegas MD. Stereoselective synthesis and biological evaluation as inhibitors of hepatitis C virus RNA polymerase of GSK3082 analogues with structural diversity at the 5-position. European Journal of Medicinal Chemistry 2019;171:401-19. [DOI: 10.1016/j.ejmech.2019.03.019] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
71 Vermehren J, Park JS, Jacobson IM, Zeuzem S. Challenges and perspectives of direct antivirals for the treatment of hepatitis C virus infection. J Hepatol. 2018;69:1178-1187. [PMID: 30006068 DOI: 10.1016/j.jhep.2018.07.002] [Cited by in Crossref: 58] [Cited by in F6Publishing: 55] [Article Influence: 14.5] [Reference Citation Analysis]
72 Ortiz GA, Trivedi HD, Nader C. Pharmacokinetics and drug interactions of medications used to treat hepatitis C virus infection in the setting of chronic kidney disease and kidney transplantation. Hemodial Int 2018;22 Suppl 1:S22-35. [PMID: 29694720 DOI: 10.1111/hdi.12648] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
73 Setten RL, Lightfoot HL, Habib NA, Rossi JJ. Development of MTL-CEBPA: Small Activating RNA Drug for Hepatocellular Carcinoma. Curr Pharm Biotechnol 2018;19:611-21. [PMID: 29886828 DOI: 10.2174/1389201019666180611093428] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 3.3] [Reference Citation Analysis]
74 Cheng VCC, Wong SC, Wong SCY, Sridhar S, Yip CCY, Chen JHK, Fung J, Chiu KHY, Ho PL, Chen S, Cheng BWC, Ho CL, Lo CM, Yuen KY. Nosocomial transmission of hepatitis C virus in a liver transplant center in Hong Kong: implication of reusable blood collection tube holder as the vehicle for transmission. Infect Control Hosp Epidemiol 2018;39:1170-7. [PMID: 30156177 DOI: 10.1017/ice.2018.175] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
75 Sezaki H, Suzuki F, Hosaka T, Fujiyama S, Kawamura Y, Akuta N, Kobayashi M, Suzuki Y, Saitoh S, Arase Y, Ikeda K, Kobayashi M, Kumada H. Initial- and re-treatment effectiveness of glecaprevir and pibrentasvir for Japanese patients with chronic hepatitis C virus-genotype 1/2/3 infections. J Gastroenterol 2019;54:916-27. [PMID: 30903385 DOI: 10.1007/s00535-019-01575-9] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
76 Zhang H, Zheng X, Li J, Liu Q, Huang XX, Ding H, Suzuki R, Muramatsu M, Song SJ. Flavonoid-triazolyl hybrids as potential anti-hepatitis C virus agents: Synthesis and biological evaluation. Eur J Med Chem 2021;218:113395. [PMID: 33838584 DOI: 10.1016/j.ejmech.2021.113395] [Reference Citation Analysis]
77 Virzì A, Roca Suarez AA, Baumert TF, Lupberger J. Oncogenic Signaling Induced by HCV Infection. Viruses 2018;10:E538. [PMID: 30279347 DOI: 10.3390/v10100538] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
78 Anasir MI, Poh CL. Structural Vaccinology for Viral Vaccine Design. Front Microbiol 2019;10:738. [PMID: 31040832 DOI: 10.3389/fmicb.2019.00738] [Cited by in Crossref: 20] [Cited by in F6Publishing: 14] [Article Influence: 6.7] [Reference Citation Analysis]
79 Li J, Feng S, Liu X, Guo M, Chen M, Chen Y, Rong L, Xia J, Zhou Y, Zhong J, Li YP. Identification of nucleotides in the 5'UTR and amino acids substitutions that are essential for the infectivity of 5'UTR-NS5A recombinant of hepatitis C virus genotype 1b (strain Con1). Virology 2018;518:253-63. [PMID: 29549787 DOI: 10.1016/j.virol.2018.03.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
80 Li C, Liang J, Xiang H, Chen H, Tian J. Effectiveness of direct-acting antivirals in maintenance hemodialysis patients complicated with chronic hepatitis C. Medicine (Baltimore) 2020;99:e23384. [PMID: 33235113 DOI: 10.1097/MD.0000000000023384] [Reference Citation Analysis]
81 Hadley S. King C, Keeney J, Guimera N, Das S, Weber M, Fochtman B, Walderhaug MO, Talwar S, Patel JA, Mazumder R, Donaldson EF. Communicating regulatory high-throughput sequencing data using BioCompute Objects. Drug Discovery Today 2022. [DOI: 10.1016/j.drudis.2022.01.007] [Reference Citation Analysis]
82 Khadempour-Arani H, Shojaeian A, Mehri-Ghahfarrokhi A, Shahraki HR, Karimi A, Dehghan A, Mobini GR. Identifying genotype profile of chronic hepatitis C infection in Southwest Iran. J Res Med Sci 2020;25:85. [PMID: 33273930 DOI: 10.4103/jrms.JRMS_524_19] [Reference Citation Analysis]
83 Suares A, Medina MV, Coso O. Autophagy in Viral Development and Progression of Cancer. Front Oncol 2021;11:603224. [PMID: 33763351 DOI: 10.3389/fonc.2021.603224] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
84 Cimini E, Bordoni V, Sacchi A, Visco-Comandini U, Montalbano M, Taibi C, Casetti R, Lalle E, D'Offizi G, Capobianchi MR, Agrati C. Intrahepatic Vγ9Vδ2 T-cells from HCV-infected patients show an exhausted phenotype but can inhibit HCV replication. Virus Res 2018;243:31-5. [PMID: 29029951 DOI: 10.1016/j.virusres.2017.10.008] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
85 Teixeira TA, Oliveira YC, Bernardes FS, Kallas EG, Duarte-Neto AN, Esteves SC, Drevet JR, Hallak J. Viral infections and implications for male reproductive health. Asian J Androl 2021;23:335-47. [PMID: 33473014 DOI: 10.4103/aja.aja_82_20] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
86 Shiryaev VA, Radchenko EV, Palyulin VA, Zefirov NS, Bormotov NI, Serova OA, Shishkina LN, Baimuratov MR, Bormasheva KM, Gruzd YA, Ivleva EA, Leonova MV, Lukashenko AV, Osipov DV, Osyanin VA, Reznikov AN, Shadrikova VA, Sibiryakova AE, Tkachenko IM, Klimochkin YN. Molecular design, synthesis and biological evaluation of cage compound-based inhibitors of hepatitis C virus p7 ion channels. Eur J Med Chem 2018;158:214-35. [PMID: 30218908 DOI: 10.1016/j.ejmech.2018.08.009] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
87 Leite C, Starosta RT, Trindade EN, Trindade MRM, Álvares-da-silva MR, Cerski CTS. Corrected integrated density: a novel method for liver elastic fibers quantification in chronic hepatitis C. Surg Exp Pathol 2020;3. [DOI: 10.1186/s42047-020-0055-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
88 Dewi SK, Ali S, Prasasty VD. Broad Spectrum Peptide Vaccine Design Against Hepatitis C Virus. Curr Comput Aided Drug Des 2019;15:120-35. [PMID: 30280672 DOI: 10.2174/1573409914666181003151222] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
89 Unfried JP, Fortes P. LncRNAs in HCV Infection and HCV-Related Liver Disease. Int J Mol Sci 2020;21:E2255. [PMID: 32214045 DOI: 10.3390/ijms21062255] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 6.5] [Reference Citation Analysis]
90 Pisano MB, Giadans CG, Flichman DM, Ré VE, Preciado MV, Valva P. Viral hepatitis update: Progress and perspectives . World J Gastroenterol 2021; 27(26): 4018-4044 [PMID: 34326611 DOI: 10.3748/wjg.v27.i26.4018] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
91 Beisel C, Herrmann M, Piecha F, Lampalzer S, Buescher G, Pischke S, Schulze zur Wiesch J. Real-world Effectiveness of Glecaprevir/Pibrentasvir (GLE/PIB) for Chronic Hepatitis C Infection: Evidence From a German Single-center Cohort Study. Hepat Mon 2021;21. [DOI: 10.5812/hepatmon.110077] [Reference Citation Analysis]
92 Medrano LM, Berenguer J, Jiménez-Sousa MA, Aldámiz-Echevarria T, Tejerina F, Diez C, Vigón L, Fernández-Rodríguez A, Resino S. ADAR1 polymorphisms are related to severity of liver fibrosis in HIV/HCV-coinfected patients. Sci Rep 2017;7:12918. [PMID: 29018269 DOI: 10.1038/s41598-017-12885-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
93 Zaongo SD, Ouyang J, Chen Y, Jiao Y, Wu H, Chen Y. HIV Infection Predisposes to Increased Chances of HBV Infection: Current Understanding of the Mechanisms Favoring HBV Infection at Each Clinical Stage of HIV Infection. Front Immunol 2022;13:853346. [DOI: 10.3389/fimmu.2022.853346] [Reference Citation Analysis]
94 Kong F, Feng B, Zhang H, Rao H, Wang J, Cong X, Wei L. Abnormal phenotypic features of IgM+B cell subsets in patients with chronic hepatitis C virus infection. Exp Ther Med 2017;14:1846-52. [PMID: 28810658 DOI: 10.3892/etm.2017.4682] [Reference Citation Analysis]
95 Shmeleva EV, Colucci F. Maternal natural killer cells at the intersection between reproduction and mucosal immunity. Mucosal Immunol 2021;14:991-1005. [PMID: 33903735 DOI: 10.1038/s41385-020-00374-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
96 Roca Suarez AA, Testoni B, Baumert TF, Lupberger J. Nucleic Acid-Induced Signaling in Chronic Viral Liver Disease. Front Immunol 2020;11:624034. [PMID: 33613561 DOI: 10.3389/fimmu.2020.624034] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
97 Qian X, Wu B, Xu C, Qi Z. Hepatitis C Virus Infection Cycle-Specific MicroRNA Profiling Reveals Stage-Specific miR-4423-3p Targets RIG-I to Facilitate Infection. Front Cell Infect Microbiol 2022;12:851917. [DOI: 10.3389/fcimb.2022.851917] [Reference Citation Analysis]
98 Uribe-Noguez LA, Ocaña-Mondragón A, Mata-Marín JA, Cázares-Cortázar A, Ribas-Aparicio RM, Gómez-Torres ME, Gaytán-Martínez J, Martínez-Rodríguez ML. Case report: Identification of recombinant HCV genotype 1b-2b by viral sequencing in two patients with treatment failure, who responded to re-treatment with sofosbuvir and daclatasvir. J Infect Chemother 2018;24:928-31. [PMID: 29773440 DOI: 10.1016/j.jiac.2018.04.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
99 Sharma AL, Singh TR, Singh LS. Understanding of HIV/AIDS in the international border area, Manipur: Northeast India. Epidemiol Infect 2019;147:e113. [PMID: 30869002 DOI: 10.1017/S0950268818003564] [Reference Citation Analysis]
100 Abdallah M, Hamed MM, Frakolaki E, Katsamakas S, Vassilaki N, Bartenschlager R, Zoidis G, Hirsch AKH, Abdel-Halim M, Abadi AH. Redesigning of the cap conformation and symmetry of the diphenylethyne core to yield highly potent pan-genotypic NS5A inhibitors with high potency and high resistance barrier. Eur J Med Chem 2021;229:114034. [PMID: 34959173 DOI: 10.1016/j.ejmech.2021.114034] [Reference Citation Analysis]
101 Raasch M, Fritsche E, Kurtz A, Bauer M, Mosig AS. Microphysiological systems meet hiPSC technology - New tools for disease modeling of liver infections in basic research and drug development. Adv Drug Deliv Rev 2019;140:51-67. [PMID: 29908880 DOI: 10.1016/j.addr.2018.06.008] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
102 Giadans CG, Ríos DA, Ameigeiras B, Haddad L, De Matteo EN, Valva P, Preciado MV. Intrahepatic immune infiltrate in chronic hepatitis B and chronic hepatitis C: Similar but not the same. J Viral Hepat 2021. [PMID: 34820942 DOI: 10.1111/jvh.13635] [Reference Citation Analysis]
103 Carty PG, McCarthy M, O'Neill SM, De Gascun CF, Harrington P, O'Neill M, Smith SM, Teljeur C, Ryan M. Laboratory-based testing for hepatitis C infection using dried blood spot samples: A systematic review and meta-analysis of diagnostic accuracy. Rev Med Virol 2021;:e2320. [PMID: 34957630 DOI: 10.1002/rmv.2320] [Reference Citation Analysis]
104 Shen C, Fan H, Ge Z, Cai W, Shao J, Dong C, Xue H, Fu Z, Li J, Zhang Y, Yue M. Efficacy and Safety of Glecaprevir/Pibrentasvir in HCV Patients With Previous Direct-Acting Antiviral Therapy Failures: A Meta-Analysis. Front Med (Lausanne) 2020;7:592472. [PMID: 33425940 DOI: 10.3389/fmed.2020.592472] [Reference Citation Analysis]
105 Wiktor S. How feasible is the global elimination of HCV infection? Lancet 2019;393:1265-7. [PMID: 30704788 DOI: 10.1016/S0140-6736(18)32750-8] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 3.3] [Reference Citation Analysis]
106 Ludwig BS, Correia JD, Kühn FE. Ferrocene derivatives as anti-infective agents. Coordination Chemistry Reviews 2019;396:22-48. [DOI: 10.1016/j.ccr.2019.06.004] [Cited by in Crossref: 26] [Cited by in F6Publishing: 10] [Article Influence: 8.7] [Reference Citation Analysis]
107 Aas CF, Vold JH, Skurtveit S, Odsbu I, Chalabianloo F, Lim AG, Johansson KA, Fadnes LT. Uptake and predictors of direct-acting antiviral treatment for hepatitis C among people receiving opioid agonist therapy in Sweden and Norway: a drug utilization study from 2014 to 2017. Subst Abuse Treat Prev Policy 2020;15:44. [PMID: 32605625 DOI: 10.1186/s13011-020-00286-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
108 Martinello M, Hajarizadeh B, Dore GJ. Observations on the launch of new drugs for hepatitis C. Aust Prescr 2018;41:4-5. [PMID: 29507451 DOI: 10.18773/austprescr.2018.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
109 Ahmad S, Shahid F, Tahir Ul Qamar M, Rehman HU, Abbasi SW, Sajjad W, Ismail S, Alrumaihi F, Allemailem KS, Almatroudi A, Ullah Saeed HF. Immuno-Informatics Analysis of Pakistan-Based HCV Subtype-3a for Chimeric Polypeptide Vaccine Design. Vaccines (Basel) 2021;9:293. [PMID: 33801143 DOI: 10.3390/vaccines9030293] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
110 Ghanaat K, Sharafi H, Alavian SM. The Efficacy and Safety of Sofosbuvir/Daclatasvir Fixed-Dose Combination in Iranian Hemodialysis Patients with Hepatitis C Virus Infection. Nephro-Urol Mon 2021;13. [DOI: 10.5812/numonthly.114049] [Reference Citation Analysis]
111 Brezzi M, Bertisch B, Roelens M, Moradpour D, Terziroli Beretta-Piccoli B, Semmo N, Müllhaupt B, Semela D, Negro F, Keiser O; Swiss Hepatitis C Cohort Study. Impact of geographic origin on access to therapy and therapy outcomes in the Swiss Hepatitis C Cohort Study. PLoS One 2019;14:e0218706. [PMID: 31233524 DOI: 10.1371/journal.pone.0218706] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
112 Lim SH, Snider J, Birimberg‐schwartz L, Ip W, Serralha JC, Botelho HM, Lopes‐pacheco M, Pinto MC, Moutaoufik MT, Zilocchi M, Laselva O, Esmaeili M, Kotlyar M, Lyakisheva A, Tang P, López Vázquez L, Akula I, Aboualizadeh F, Wong V, Grozavu I, Opacak‐bernardi T, Yao Z, Mendoza M, Babu M, Jurisica I, Gonska T, Bear CE, Amaral MD, Stagljar I. CFTR interactome mapping using the mammalian membrane two‐hybrid high‐throughput screening system. Molecular Systems Biology 2022;18. [DOI: 10.15252/msb.202110629] [Reference Citation Analysis]
113 Liu Y, Li J, Gu Y, Ma L, Cen S, Peng Z, Hu L. Synthesis and structure-activity relationship study of new biaryl amide derivatives and their inhibitory effects against hepatitis C virus. Eur J Med Chem 2022;228:114033. [PMID: 34883293 DOI: 10.1016/j.ejmech.2021.114033] [Reference Citation Analysis]
114 Devi P, Punga T, Bergqvist A. Activation of the Ca2+/NFAT Pathway by Assembly of Hepatitis C Virus Core Protein into Nucleocapsid-like Particles. Viruses 2022;14:761. [DOI: 10.3390/v14040761] [Reference Citation Analysis]
115 Moreno-Cubero E, Subirá D, Sanz-de-Villalobos E, Parra-Cid T, Madejón A, Miquel J, Olveira A, González-Praetorius A, García-Samaniego J, Larrubia JR. According to Hepatitis C Virus (HCV) Infection Stage, Interleukin-7 Plus 4-1BB Triggering Alone or Combined with PD-1 Blockade Increases TRAF1low HCV-Specific CD8+ Cell Reactivity. J Virol 2018;92:e01443-17. [PMID: 29093082 DOI: 10.1128/JVI.01443-17] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
116 Singh D, Soni S, Khan S, Sarangi AN, Yennamalli RM, Aggarwal R, Veerapu NS. Genome-Wide Mutagenesis of Hepatitis C Virus Reveals Ability of Genome To Overcome Detrimental Mutations. J Virol 2020;94:e01327-19. [PMID: 31723027 DOI: 10.1128/JVI.01327-19] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
117 Cabral MS, Santos TPS, Santos PL, Schinoni MI, Oliveira IS, Pereira AB, Atta AM, Sousa-Atta MLB. Immune response of Th17-associated cytokines by peripheral blood mononuclear cells from patients with chronic hepatitis C virus infection. Cytokine 2018;102:200-5. [PMID: 28969940 DOI: 10.1016/j.cyto.2017.09.015] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
118 Tsai WL, Wang CF, Cheng JS, Chen WC, Bair MJ, Lo CC. Sofosbuvir-based regimen for genotype 2 HCV infected patients in Taiwan: A real world experience. PLoS One 2020;15:e0227424. [PMID: 31923251 DOI: 10.1371/journal.pone.0227424] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
119 Pihl AF, Offersgaard AF, Mathiesen CK, Prentoe J, Fahnøe U, Krarup H, Bukh J, Gottwein JM. High density Huh7.5 cell hollow fiber bioreactor culture for high-yield production of hepatitis C virus and studies of antivirals. Sci Rep 2018;8:17505. [PMID: 30504788 DOI: 10.1038/s41598-018-35010-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
120 Adeboyejo K, Grosche VR, José DP, Ferreira GM, Shimizu JF, King BJ, Tarr AW, Soares MMCN, Ball JK, Mcclure CP, Jardim ACG. Simultaneous determination of HCV genotype and NS5B resistance associated substitutions using dried serum spots from São Paulo state, Brazil. Access Microbiology 2022;4. [DOI: 10.1099/acmi.0.000326] [Reference Citation Analysis]
121 Martinello M, Hajarizadeh B, Grebely J, Dore GJ, Matthews GV. Management of acute HCV infection in the era of direct-acting antiviral therapy. Nat Rev Gastroenterol Hepatol. 2018;15:412-424. [PMID: 29773899 DOI: 10.1038/s41575-018-0026-5] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 11.0] [Reference Citation Analysis]
122 Cho YK, Kim S, Kim HO, Choi DS, Kim HS, Park Y. Comparative evaluation of Elecsys, Atellica, and Alinity assays for measuring the anti-Hepatitis C virus (HCV) antibody. J Clin Virol 2021;141:104910. [PMID: 34273861 DOI: 10.1016/j.jcv.2021.104910] [Reference Citation Analysis]
123 Karlsen TH, Sheron N, Zelber-Sagi S, Carrieri P, Dusheiko G, Bugianesi E, Pryke R, Hutchinson SJ, Sangro B, Martin NK, Cecchini M, Dirac MA, Belloni A, Serra-Burriel M, Ponsioen CY, Sheena B, Lerouge A, Devaux M, Scott N, Hellard M, Verkade HJ, Sturm E, Marchesini G, Yki-Järvinen H, Byrne CD, Targher G, Tur-Sinai A, Barrett D, Ninburg M, Reic T, Taylor A, Rhodes T, Treloar C, Petersen C, Schramm C, Flisiak R, Simonova MY, Pares A, Johnson P, Cucchetti A, Graupera I, Lionis C, Pose E, Fabrellas N, Ma AT, Mendive JM, Mazzaferro V, Rutter H, Cortez-Pinto H, Kelly D, Burton R, Lazarus JV, Ginès P, Buti M, Newsome PN, Burra P, Manns MP. The EASL-Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality. Lancet 2022;399:61-116. [PMID: 34863359 DOI: 10.1016/S0140-6736(21)01701-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
124 Romano A, Angeli P, Piovesan S, Noventa F, Anastassopoulos G, Chemello L, Cavalletto L, Gambato M, Russo FP, Burra P, Vincenzi V, Scotton PG, Panese S, Tempesta D, Bertin T, Carrara M, Carlotto A, Capra F, Carolo G, Scroccaro G, Alberti A. Newly diagnosed hepatocellular carcinoma in patients with advanced hepatitis C treated with DAAs: A prospective population study. J Hepatol. 2018;69:345-352. [PMID: 29551707 DOI: 10.1016/j.jhep.2018.03.009] [Cited by in Crossref: 66] [Cited by in F6Publishing: 67] [Article Influence: 16.5] [Reference Citation Analysis]
125 Deng L, Jiang W, Wang X, Merz A, Hiet MS, Chen Y, Pan X, Jiu Y, Yang Y, Yu B, He Y, Tu Z, Niu J, Bartenschlager R, Long G. Syntenin regulates hepatitis C virus sensitivity to neutralizing antibody by promoting E2 secretion through exosomes. J Hepatol 2019;71:52-61. [PMID: 30880226 DOI: 10.1016/j.jhep.2019.03.006] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 4.7] [Reference Citation Analysis]
126 Gamal-AbdelNaser A, Mohammed WS, ElHefnawi M, AbdAllah M, Elsharkawy A, Zahran FM. The oral microbiome of treated and untreated chronic HCV infection: A preliminary study. Oral Dis 2021. [PMID: 34396636 DOI: 10.1111/odi.14007] [Reference Citation Analysis]
127 Soriano V, Fernandez-Montero JV, de Mendoza C, Benitez-Gutierrez L, Peña JM, Arias A, Barreiro P. Treatment of hepatitis C with new fixed dose combinations. Expert Opin Pharmacother 2017;18:1235-42. [PMID: 28644739 DOI: 10.1080/14656566.2017.1346609] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 3.4] [Reference Citation Analysis]
128 El Missiri AM, Rayan MM, Awad MM, El Desoky AI. Assessing the impact of a combination of sofosbuvir and daclatasvir treatment for hepatitis C virus infection on heart rate, rhythm and heart rate variability using 24-hour ECG monitoring. Egypt Heart J 2020;72:37. [PMID: 32613565 DOI: 10.1186/s43044-020-00070-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
129 Cai D, Liu L, Tian B, Fu X, Yang Q, Chen J, Zhang Y, Fang J, Shen L, Wang Y, Gou L, Zuo Z. Dual-Role Ubiquitination Regulation Shuttling the Entire Life Cycle of the Flaviviridae. Front Microbiol 2022;13:835344. [DOI: 10.3389/fmicb.2022.835344] [Reference Citation Analysis]
130 Fabrizi F, Messa P. The epidemiology of HCV infection in patients with advanced CKD/ESRD: A global perspective. Semin Dial 2019;32:93-8. [PMID: 30536715 DOI: 10.1111/sdi.12757] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
131 Lanini S, Pisapia R, Capobianchi MR, Ippolito G. Global epidemiology of viral hepatitis and national needs for complete control. Expert Rev Anti Infect Ther 2018;16:625-39. [PMID: 30067107 DOI: 10.1080/14787210.2018.1505503] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 3.5] [Reference Citation Analysis]
132 Badshah Y, Arshad N, Khan M, Jannat A, Hayat H. Association of Interleukin-4 (-590 C/T) and Interleukin-6 (-174 G/C) Polymorphism in Pathogenesis and Prognosis of Hepatitis C Virus Infection. Journal of Interferon & Cytokine Research 2018;38:559-65. [DOI: 10.1089/jir.2018.0081] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
133 Yamazaki K, Macaulay D, Song Y, Sanchez Gonzalez Y. Clinical and Economic Burden of Patients with Chronic Hepatitis C with Versus Without Antiviral Treatment in Japan: An Observational Cohort Study Using Hospital Claims Data. Infect Dis Ther 2019;8:285-99. [PMID: 30771220 DOI: 10.1007/s40121-019-0234-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
134 Rowe IA. Histological Endpoints for Nonalcoholic Steatohepatitis Trials: Lights and Shadows. Semin Liver Dis 2020;40:339-45. [PMID: 32906165 DOI: 10.1055/s-0040-1709491] [Reference Citation Analysis]
135 Applegate TL, Fajardo E, Sacks JA. Hepatitis C Virus Diagnosis and the Holy Grail. Infectious Disease Clinics of North America 2018;32:425-45. [DOI: 10.1016/j.idc.2018.02.010] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 7.5] [Reference Citation Analysis]
136 Torres-vázquez B, María de Lucas A, García-crespo C, Antonio García-martín J, Fragoso A, Fernández-algar M, Perales C, Domingo E, Moreno M, Briones C. In vitro selection of high affinity DNA and RNA aptamers that detect hepatitis C virus core protein of genotypes 1 to 4 and inhibit virus production in cell culture. Journal of Molecular Biology 2022. [DOI: 10.1016/j.jmb.2022.167501] [Reference Citation Analysis]
137 AlMalki WH, Shahid I, Abdalla AN, Johargy AK, Ahmed M, Hassan S. Virological surveillance, molecular phylogeny, and evolutionary dynamics of hepatitis C virus subtypes 1a and 4a isolates in patients from Saudi Arabia. Saudi J Biol Sci 2021;28:1664-77. [PMID: 33732052 DOI: 10.1016/j.sjbs.2020.11.089] [Reference Citation Analysis]
138 Hu JH, Chen MY, Yeh CT, Chiu WN, Chiang MS, Chang ML. Effects of gender and age on prevalence of cholelithiasis in patients with chronic HCV infection: A community-based cross-sectional study in an HCV-hyperendemic area. Medicine (Baltimore) 2018;97:e10846. [PMID: 29851796 DOI: 10.1097/MD.0000000000010846] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
139 Santangelo L, Bordoni V, Montaldo C, Cimini E, Zingoni A, Battistelli C, D'Offizi G, Capobianchi MR, Santoni A, Tripodi M, Agrati C. Hepatitis C virus direct-acting antivirals therapy impacts on extracellular vesicles microRNAs content and on their immunomodulating properties. Liver Int 2018;38:1741-50. [PMID: 29359389 DOI: 10.1111/liv.13700] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 3.5] [Reference Citation Analysis]
140 Dent M, Hamorsky K, Vausselin T, Dubuisson J, Miyata Y, Morikawa Y, Matoba N. Safety and Efficacy of Avaren-Fc Lectibody Targeting HCV High-Mannose Glycans in a Human Liver Chimeric Mouse Model. Cell Mol Gastroenterol Hepatol 2021;11:185-98. [PMID: 32861832 DOI: 10.1016/j.jcmgh.2020.08.009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
141 Garcia-Broncano P, Medrano LM, Berenguer J, González-García J, Jiménez-Sousa MÁ, Carrero A, Hontañón V, Guardiola JM, Crespo M, Quereda C, Sanz J, García-Gómez AB, Jimenez JL, Resino S; GESIDA 3603b Study Group. Dysregulation of the Immune System in HIV/HCV-Coinfected Patients According to Liver Stiffness Status. Cells 2018;7:E196. [PMID: 30400258 DOI: 10.3390/cells7110196] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
142 Boukadida C, Fritz M, Blumen B, Fogeron ML, Penin F, Martin A. NS2 proteases from hepatitis C virus and related hepaciviruses share composite active sites and previously unrecognized intrinsic proteolytic activities. PLoS Pathog 2018;14:e1006863. [PMID: 29415072 DOI: 10.1371/journal.ppat.1006863] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
143 Barriocanal M, Fortes P. Long Non-coding RNAs in Hepatitis C Virus-Infected Cells. Front Microbiol. 2017;8:1833. [PMID: 29033906 DOI: 10.3389/fmicb.2017.01833] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
144 Giannakopoulou E, Pardali V, Zoidis G. Metal-chelating agents against viruses and parasites. Future Med Chem 2018;10:1283-5. [PMID: 29719970 DOI: 10.4155/fmc-2018-0100] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
145 Pfaender S, Helfritz FA, Siddharta A, Todt D, Behrendt P, Heyden J, Riebesehl N, Willmann W, Steinmann J, Münch J, Ciesek S, Steinmann E. Environmental Stability and Infectivity of Hepatitis C Virus (HCV) in Different Human Body Fluids. Front Microbiol 2018;9:504. [PMID: 29636728 DOI: 10.3389/fmicb.2018.00504] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
146 Wu N, Rao HY, Yang WB, Gao ZL, Yang RF, Fei R, Gao YH, Jin Q, Wei L. Impact of hepatitis C virus genotype 3 on liver disease progression in a Chinese national cohort. Chin Med J (Engl) 2020;133:253-61. [PMID: 31934936 DOI: 10.1097/CM9.0000000000000629] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
147 Refolo G, Ciccosanti F, Di Rienzo M, Basulto Perdomo A, Romani M, Alonzi T, Tripodi M, Ippolito G, Piacentini M, Fimia GM. Negative Regulation of Mitochondrial Antiviral Signaling Protein-Mediated Antiviral Signaling by the Mitochondrial Protein LRPPRC During Hepatitis C Virus Infection. Hepatology 2019;69:34-50. [PMID: 30070380 DOI: 10.1002/hep.30149] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 4.8] [Reference Citation Analysis]
148 Zhang Y, Zhao X, Zou J, Yuan Z, Yi Z. Dual role of the amphipathic helix of hepatitis C virus NS5A in the viral polyprotein cleavage and replicase assembly. Virology 2019;535:283-96. [PMID: 31369938 DOI: 10.1016/j.virol.2019.07.017] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
149 Deng L, Hernandez N, Zhong L, Holcomb DD, Yan H, Virata ML, Tarafdar S, Xu Y, He Y, Struble E, Alter HJ, Zhang P. A conserved epitope III on hepatitis C virus E2 protein has alternate conformations facilitating cell binding or virus neutralization. Proc Natl Acad Sci U S A 2021;118:e2104242118. [PMID: 34260404 DOI: 10.1073/pnas.2104242118] [Reference Citation Analysis]
150 Laugel E, Hartard C, Jeulin H, Berger S, Venard V, Bronowicki JP, Schvoerer E. Full-length genome sequencing of RNA viruses-How the approach can enlighten us on hepatitis C and hepatitis E viruses. Rev Med Virol 2021;31:e2197. [PMID: 34260779 DOI: 10.1002/rmv.2197] [Reference Citation Analysis]
151 Carvalho RF, Atta AM, de Oliveira IS, Santos TPS, Santos JPA, Schinoni MI, de Sousa-Atta MLB. Adiponectin levels and insulin resistance among patients with chronic hepatitis C. Acta Trop. 2018;178:258-263. [PMID: 29217381 DOI: 10.1016/j.actatropica.2017.12.004] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
152 Crouchet E, Wrensch F, Schuster C, Zeisel MB, Baumert TF. Host-targeting therapies for hepatitis C virus infection: current developments and future applications. Therap Adv Gastroenterol 2018;11:1756284818759483. [PMID: 29619090 DOI: 10.1177/1756284818759483] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 4.5] [Reference Citation Analysis]
153 Yasser MB, Abdellatif M, Emad E, Jafer A, Ahmed S, Nageb L, Abdelshafy H, Al-Anany AM, Al-Arab MAE, Gibriel AA. Circulatory miR-221 & miR-542 expression profiles as potential molecular biomarkers in Hepatitis C Virus mediated liver cirrhosis and hepatocellular carcinoma. Virus Res 2021;296:198341. [PMID: 33607184 DOI: 10.1016/j.virusres.2021.198341] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
154 Luo X, Xue B, Feng G, Zhang J, Lin B, Zeng P, Li H, Yi H, Zhang XL, Zhu H, Nie Z. Lighting up the Native Viral RNA Genome with a Fluorogenic Probe for the Live-Cell Visualization of Virus Infection. J Am Chem Soc 2019;141:5182-91. [PMID: 30860368 DOI: 10.1021/jacs.8b10265] [Cited by in Crossref: 35] [Cited by in F6Publishing: 28] [Article Influence: 11.7] [Reference Citation Analysis]
155 Aldunate F, Echeverría N, Chiodi D, López P, Sánchez-Cicerón A, Soñora M, Cristina J, Moratorio G, Hernández N, Moreno P. Resistance-associated substitutions and response to treatment in a chronic hepatitis C virus infected-patient: an unusual virological response case report. BMC Infect Dis 2021;21:387. [PMID: 33902462 DOI: 10.1186/s12879-021-06080-0] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
156 Fu K, Wang C, Ma C, Zhou H, Li Y. The Potential Application of Chinese Medicine in Liver Diseases: A New Opportunity. Front Pharmacol 2021;12:771459. [PMID: 34803712 DOI: 10.3389/fphar.2021.771459] [Reference Citation Analysis]
157 Mahmoud AA, Hassan MH, Ghweil AA, Abdelrahman A, Mohammad AN, Ameen HH. Urinary 8-hydroxydeoxyguanosine in relation to XRCC1 rs25487 G/A (Arg399Gln) and OGG1 rs1052133 C/G (Ser326Cys) DNA repair genes polymorphisms in patients with chronic hepatitis C and related hepatocellular carcinoma. Cancer Manag Res 2019;11:5343-51. [PMID: 31354343 DOI: 10.2147/CMAR.S209112] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.7] [Reference Citation Analysis]
158 Kremsdorf D, Strick-Marchand H. Modeling hepatitis virus infections and treatment strategies in humanized mice. Curr Opin Virol 2017;25:119-25. [PMID: 28858692 DOI: 10.1016/j.coviro.2017.07.029] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
159 Mosa AI, AbouHaidar MG, Urbanowicz RA, Tavis JE, Ball JK, Feld JJ. Role of HVR1 sequence similarity in the cross-genotypic neutralization of HCV. Virol J 2020;17:140. [PMID: 32948191 DOI: 10.1186/s12985-020-01408-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
160 Rehman MU, Farooq A, Ali R, Bashir S, Bashir N, Majeed S, Taifa S, Ahmad SB, Arafah A, Sameer AS, Khan R, Qamar W, Rasool S, Ahmad A. Preclinical Evidence for the Pharmacological Actions of Glycyrrhizic Acid: A Comprehensive Review. Curr Drug Metab 2020;21:436-65. [PMID: 32562521 DOI: 10.2174/1389200221666200620204914] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
161 Lee H, Jarhad DB, Yu J, Lee C, Jeong LS. Asymmetric Synthesis of 2'-C-Methyl-4'-selenonucleosides as Anti-Hepatitis C Virus Agents. J Org Chem 2019;84:14414-26. [PMID: 31608633 DOI: 10.1021/acs.joc.9b01462] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
162 Lee S, Yoon H, Han J, Jang KL. Hepatitis C virus core protein inhibits hepatitis B virus replication by downregulating HBx levels via Siah-1-mediated proteasomal degradation during coinfection. J Gen Virol 2021;102. [PMID: 34882535 DOI: 10.1099/jgv.0.001701] [Reference Citation Analysis]
163 Vantourout JC, Li L, Bendito-moll E, Chabbra S, Arrington K, Bode BE, Isidro-llobet A, Kowalski JA, Nilson MG, Wheelhouse KMP, Woodard JL, Xie S, Leitch DC, Watson AJB. Mechanistic Insight Enables Practical, Scalable, Room Temperature Chan–Lam N -Arylation of N -Aryl Sulfonamides. ACS Catal 2018;8:9560-6. [DOI: 10.1021/acscatal.8b03238] [Cited by in Crossref: 28] [Cited by in F6Publishing: 18] [Article Influence: 7.0] [Reference Citation Analysis]
164 Neufeldt CJ, Cortese M, Acosta EG, Bartenschlager R. Rewiring cellular networks by members of the Flaviviridae family. Nat Rev Microbiol. 2018;16:125-142. [PMID: 29430005 DOI: 10.1038/nrmicro.2017.170] [Cited by in Crossref: 142] [Cited by in F6Publishing: 130] [Article Influence: 47.3] [Reference Citation Analysis]
165 Santos VCD, Schinoni MI, Oliveira IS, Atta MLS, Atta AM. IgG1 and IgG4 antibodies against Core and NS3 antigens of hepatitis C virus. Rev Soc Bras Med Trop. 2019;52:e20180491. [PMID: 30843970 DOI: 10.1590/0037-8682-0491-2018] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
166 Ponziani FR, Putignani L, Paroni Sterbini F, Petito V, Picca A, Del Chierico F, Reddel S, Calvani R, Marzetti E, Sanguinetti M, Gasbarrini A, Pompili M. Influence of hepatitis C virus eradication with direct-acting antivirals on the gut microbiota in patients with cirrhosis. Aliment Pharmacol Ther 2018;48:1301-11. [PMID: 30345704 DOI: 10.1111/apt.15004] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 7.5] [Reference Citation Analysis]
167 García-Nicolás O, V'kovski P, Vielle NJ, Ebert N, Züst R, Portmann J, Stalder H, Gaschen V, Vieyres G, Stoffel M, Schweizer M, Summerfield A, Engler O, Pietschmann T, Todt D, Alves MP, Thiel V, Pfaender S. The Small-Compound Inhibitor K22 Displays Broad Antiviral Activity against Different Members of the Family Flaviviridae and Offers Potential as a Panviral Inhibitor. Antimicrob Agents Chemother 2018;62:e01206-18. [PMID: 30181371 DOI: 10.1128/AAC.01206-18] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
168 Smith S, Honegger JR, Walker C. T-Cell Immunity against the Hepatitis C Virus: A Persistent Research Priority in an Era of Highly Effective Therapy. Cold Spring Harb Perspect Med 2021;11:a036954. [PMID: 32205413 DOI: 10.1101/cshperspect.a036954] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
169 Groaz E, De Clercq E, Herdewijn P. Anno 2021: Which antivirals for the coming decade? Annu Rep Med Chem 2021;57:49-107. [PMID: 34744210 DOI: 10.1016/bs.armc.2021.09.004] [Reference Citation Analysis]
170 Pedlar A, Sandhu PJ. Promoting treatment for hepatitis C in people who inject drugs: A review of the barriers and opportunities. J Am Assoc Nurse Pract 2020;32:563-8. [PMID: 31425374 DOI: 10.1097/JXX.0000000000000269] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
171 Soriano V, Benítez-Gutiérrez L, Arias A, Carrasco I, Barreiro P, Peña JM, de Mendoza C. Evaluation of sofosbuvir, velpatasvir plus voxilaprevir as fixed-dose co-formulation for treating hepatitis C. Expert Opin Drug Metab Toxicol 2017;13:1015-22. [PMID: 28753040 DOI: 10.1080/17425255.2017.1359254] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
172 Berggren KA, Suzuki S, Ploss A. Animal Models Used in Hepatitis C Virus Research. Int J Mol Sci 2020;21:E3869. [PMID: 32485887 DOI: 10.3390/ijms21113869] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
173 Ortega-prieto AM, Dorner M. Novel methods to prevent HCV transmission. Future Virology 2017;12:471-3. [DOI: 10.2217/fvl-2017-0072] [Reference Citation Analysis]
174 Lee J, Song CH. Effect of Reactive Oxygen Species on the Endoplasmic Reticulum and Mitochondria during Intracellular Pathogen Infection of Mammalian Cells. Antioxidants (Basel) 2021;10:872. [PMID: 34071633 DOI: 10.3390/antiox10060872] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
175 Ma Y, Frutos-Beltrán E, Kang D, Pannecouque C, De Clercq E, Menéndez-Arias L, Liu X, Zhan P. Medicinal chemistry strategies for discovering antivirals effective against drug-resistant viruses. Chem Soc Rev 2021;50:4514-40. [PMID: 33595031 DOI: 10.1039/d0cs01084g] [Cited by in Crossref: 11] [Cited by in F6Publishing: 4] [Article Influence: 11.0] [Reference Citation Analysis]
176 Stegmann KM, Dickmanns A, Heinen N, Blaurock C, Karrasch T, Breithaupt A, Klopfleisch R, Uhlig N, Eberlein V, Issmail L, Herrmann ST, Schreieck A, Peelen E, Kohlhof H, Sadeghi B, Riek A, Speakman JR, Groß U, Görlich D, Vitt D, Müller T, Grunwald T, Pfaender S, Balkema-Buschmann A, Dobbelstein M. Inhibitors of dihydroorotate dehydrogenase cooperate with Molnupiravir and N4-hydroxycytidine to suppress SARS-CoV-2 replication. iScience 2022;:104293. [PMID: 35492218 DOI: 10.1016/j.isci.2022.104293] [Reference Citation Analysis]
177 Johnson J, Freedman H, Logan M, Wong JAJ, Hockman D, Chen C, He J, Beard MR, Eyre NS, Baumert TF, Tyrrell DL, Law JLM, Houghton M. A Recombinant Hepatitis C Virus Genotype 1a E1/E2 Envelope Glycoprotein Vaccine Elicits Antibodies That Differentially Neutralize Closely Related 2a Strains through Interactions of the N-Terminal Hypervariable Region 1 of E2 with Scavenger Receptor B1. J Virol 2019;93:e00810-19. [PMID: 31462563 DOI: 10.1128/JVI.00810-19] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
178 Kim JH, Lee CH, Lee SW. Exosomal Transmission of MicroRNA from HCV Replicating Cells Stimulates Transdifferentiation in Hepatic Stellate Cells. Mol Ther Nucleic Acids. 2019;14:483-497. [PMID: 30753992 DOI: 10.1016/j.omtn.2019.01.006] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 9.3] [Reference Citation Analysis]
179 Grégoire Y, Delage G, Custer B, Rochette S, Renaud C, Lewin A, Germain M. Cost-effectiveness of pathogen reduction technology for plasma and platelets in Québec: A focus on potential emerging pathogens. Transfusion 2022. [PMID: 35560238 DOI: 10.1111/trf.16926] [Reference Citation Analysis]
180 Shunmugam L, Ramharack P, Soliman MES. Road Map for the Structure-Based Design of Selective Covalent HCV NS3/4A Protease Inhibitors. Protein J 2017;36:397-406. [PMID: 28815420 DOI: 10.1007/s10930-017-9736-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
181 Amaddeo G, Nguyen CT, Maillé P, Mulé S, Luciani A, Machou C, Rodrigues A, Regnault H, Mallat A, Laurent A, Lafdil F, Hézode C, Pawlotsky JM, Calderaro J. Intrahepatic immune changes after hepatitis c virus eradication by direct-acting antiviral therapy. Liver Int 2020;40:74-82. [PMID: 31444947 DOI: 10.1111/liv.14226] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
182 Sharma S, Mukherjee D, Nair RK, Datt B, Rao A. Role of Direct Antiviral Agents in Treatment of Chronic Hepatitis C Infection in Renal Transplant Recipients. J Transplant 2018;2018:7579689. [PMID: 29796311 DOI: 10.1155/2018/7579689] [Cited by in Crossref: 3] [Article Influence: 0.8] [Reference Citation Analysis]
183 Gadhachanda VR, Eastman KJ, Wang Q, Phadke AS, Patel D, Yang W, Marlor CW, Deshpande M, Huang M, Wiles JA. Ferrocene-based inhibitors of hepatitis C virus replication that target NS5A with low picomolar in vitro antiviral activity. Bioorg Med Chem Lett 2018;28:3463-71. [PMID: 30290989 DOI: 10.1016/j.bmcl.2018.09.023] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
184 Martínez-Román P, López-Huertas MR, Crespo-Bermejo C, Arca-Lafuente S, Cortegano I, Valle-Millares D, Gaspar ML, Martín-Carbonero L, Domínguez-Domínguez L, Ryan P, de Los Santos I, de la Fuente-Moral S, Fernández-Rodríguez A, Coiras M, Briz V. Hepatitis C Virus Influences HIV-1 Viral Splicing in Coinfected Patients. J Clin Med 2020;9:E2091. [PMID: 32635221 DOI: 10.3390/jcm9072091] [Reference Citation Analysis]
185 Castro GLC, Amoras EDGS, Araújo MSM, Conde SRSDS, Vallinoto ACR. Hepatitis C virus genotypes and associated risk factors in the state of Pará, Northern Brazil. Braz J Infect Dis 2020;24:304-9. [PMID: 32735876 DOI: 10.1016/j.bjid.2020.06.010] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
186 Kardani K, Basimi P, Fekri M, Bolhassani A. Antiviral therapy for the sexually transmitted viruses: recent updates on vaccine development. Expert Rev Clin Pharmacol 2020;13:1001-46. [PMID: 32838584 DOI: 10.1080/17512433.2020.1814743] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
187 Grau-López L, Marcos-Fosch C, Daigre C, Palma-Alvarez RF, Rando-Segura A, Llaneras J, Perea-Ortueta M, Rodriguez-Frias F, Martínez-Luna N, Riveiro-Barciela M, Ramos-Quiroga JA, Colom J, Esteban R, Buti M. Barriers to linkage to care in hepatitis C patients with substance use disorders and dual diagnoses, despite centralized management. Therap Adv Gastroenterol 2021;14:17562848211016563. [PMID: 34471422 DOI: 10.1177/17562848211016563] [Reference Citation Analysis]
188 Yang Y, Wu FP, Wang WJ, Shi JJ, Li YP, Zhang X, Dang SS. Real life efficacy and safety of direct-acting antiviral therapy for treatment of patients infected with hepatitis C virus genotypes 1, 2 and 3 in northwest China. World J Gastroenterol 2019; 25(44): 6551-6560 [PMID: 31802834 DOI: 10.3748/wjg.v25.i44.6551] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
189 Zafar U, Hasan A, Aslam B, Khalid Z, Baig MU, Akram S. The Frequency of Hepatitis C and its Risk Factors Among Health Care Providers at Tehsil Headquarter Hospital, Hasilpur, Pakistan. Cureus 2018;10:e3176. [PMID: 30357086 DOI: 10.7759/cureus.3176] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
190 Noroozi-aghideh A, Kheirandish M. Human cord blood-derived viral pathogens as the potential threats to the hematopoietic stem cell transplantation safety: A mini review. World J Stem Cells 2019; 11(2): 73-83 [PMID: 30842806 DOI: 10.4252/wjsc.v11.i2.73] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
191 Blázquez AB, Saiz JC. Potential for Protein Kinase Pharmacological Regulation in Flaviviridae Infections. Int J Mol Sci 2020;21:E9524. [PMID: 33333737 DOI: 10.3390/ijms21249524] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
192 Aldámiz-Echevarría T, Resino S, Bellón JM, Jiménez-Sousa MA, Miralles P, Medrano LM, Carrero A, Díez C, Pérez-Latorre L, Fanciulli C, Garcia-Broncano P, Berenguer J. European mitochondrial haplogroups predict liver-related outcomes in patients coinfected with HIV and HCV: a retrospective study. J Transl Med 2019;17:244. [PMID: 31349790 DOI: 10.1186/s12967-019-1997-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
193 Zhang Z, Rong L, Li YP. Flaviviridae Viruses and Oxidative Stress: Implications for Viral Pathogenesis. Oxid Med Cell Longev 2019;2019:1409582. [PMID: 31531178 DOI: 10.1155/2019/1409582] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 7.0] [Reference Citation Analysis]
194 Yang X, Ding T, Huang H, Xu Y, Yu J, Chen Z. Development and validation of a simple and rapid method for hepatitis C virus genotyping based on one-step RT-qPCR. Exp Ther Med 2020;20:2284-90. [PMID: 32765706 DOI: 10.3892/etm.2020.8912] [Reference Citation Analysis]
195 Buti M, Domínguez-Hernández R, Casado MÁ, Sabater E, Esteban R. Healthcare value of implementing hepatitis C screening in the adult general population in Spain. PLoS One 2018;13:e0208036. [PMID: 30485377 DOI: 10.1371/journal.pone.0208036] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
196 Poordad F, Bennett M, Sepe TE, Cohen E, Reindollar RW, Everson G, Phillips RW, Siddique A, Sullivan JG, Pilot-Matias T, Abunimeh M, Cohen DE, Younes Z. Ombitasvir/paritaprevir/ritonavir and dasabuvir with or without sofosbuvir for patients with hepatitis C virus genotype 1 infection who failed a prior course of direct-acting antiviral therapy. J Med Virol 2019;91:1307-12. [PMID: 30840774 DOI: 10.1002/jmv.25448] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
197 Fierro NA, Rivera-Toledo E, Ávila-Horta F, Anaya-Covarrubias JY, Mendlovic F. Scavenger Receptors in the Pathogenesis of Viral Infections. Viral Immunol 2022. [PMID: 35319302 DOI: 10.1089/vim.2021.0167] [Reference Citation Analysis]